Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest

John Carroll

Editor & Founder

Biogen scored a big win at the FDA today as regulators accepted their application for the controversial Alzheimer’s drug aducanumab and gave it a priority …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest

John Carroll

Editor & Founder

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bio­gen scores a pri­or­i­ty re­view for its Alzheimer's drug ad­u­canum­ab, mov­ing one gi­ant leap for­ward in its con­tro­ver­sial quest

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest

CagriSema’s weight loss data disappointed. What does Novo do next?

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify